Clene Future Growth
Future criteria checks 2/6
Clene is forecast to grow earnings and revenue by 54.8% and 66.3% per annum respectively. EPS is expected to grow by 55.4% per annum. Return on equity is forecast to be -31.6% in 3 years.
Key information
54.8%
Earnings growth rate
55.4%
EPS growth rate
| Biotechs earnings growth | 23.2% |
| Revenue growth rate | 66.3% |
| Future return on equity | -31.6% |
| Analyst coverage | Low |
| Last updated | 26 Apr 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 39 | -38 | -15 | -13 | 4 |
| 12/31/2025 | 5 | -50 | -57 | -42 | 5 |
| 12/31/2024 | 0 | -43 | -41 | -34 | 5 |
| 12/31/2023 | 1 | -50 | -31 | -30 | N/A |
| 9/30/2023 | 1 | -40 | -33 | -31 | N/A |
| 6/30/2023 | 1 | -49 | -36 | -32 | N/A |
| 3/31/2023 | 1 | -28 | -40 | -35 | N/A |
| 12/31/2022 | 0 | -30 | -44 | -39 | N/A |
| 9/30/2022 | 0 | -24 | -45 | -41 | N/A |
| 6/30/2022 | 0 | 15 | -42 | -40 | N/A |
| 3/31/2022 | 1 | 17 | -41 | -39 | N/A |
| 12/31/2021 | 1 | -10 | -36 | -35 | N/A |
| 9/30/2021 | 1 | -13 | -32 | -31 | N/A |
| 6/30/2021 | 1 | -53 | -32 | -31 | N/A |
| 3/31/2021 | 0 | -55 | -25 | -25 | N/A |
| 12/31/2020 | 0 | -19 | -19 | -19 | N/A |
| 9/30/2020 | 0 | -24 | -17 | -16 | N/A |
| 6/30/2020 | 0 | -19 | -12 | -12 | N/A |
| 3/31/2020 | 0 | -16 | -13 | -13 | N/A |
| 12/31/2019 | N/A | -16 | -13 | -13 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLNN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CLNN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CLNN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CLNN's revenue (66.3% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: CLNN's revenue (66.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CLNN is forecast to be unprofitable in 3 years.